- Home
- PHAR vs MNTK Comparison
PHAR vs MNTK Comparison
Compare PHAR & MNTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- MNTK
- Stock Information
- Founded
- PHAR 1988
- MNTK 1980
- Country
- PHAR Netherlands
- MNTK United States
- Employees
- PHAR N/A
- MNTK N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- MNTK Natural Gas Distribution
- Sector
- PHAR Health Care
- MNTK Utilities
- Exchange
- PHAR Nasdaq
- MNTK Nasdaq
- Market Cap
- PHAR 718.1M
- MNTK 269.2M
- IPO Year
- PHAR N/A
- MNTK 2021
- Fundamental
- Price
- PHAR $10.27
- MNTK $2.71
- Analyst Decision
- PHAR Strong Buy
- MNTK Hold
- Analyst Count
- PHAR 3
- MNTK 3
- Target Price
- PHAR $30.00
- MNTK $3.33
- AVG Volume (30 Days)
- PHAR 4.3K
- MNTK 221.6K
- Earning Date
- PHAR 07-31-2025
- MNTK 08-07-2025
- Dividend Yield
- PHAR N/A
- MNTK N/A
- EPS Growth
- PHAR N/A
- MNTK N/A
- EPS
- PHAR N/A
- MNTK 0.05
- Revenue
- PHAR $320,708,000.00
- MNTK $179,552,000.00
- Revenue This Year
- PHAR $13.31
- MNTK $3.00
- Revenue Next Year
- PHAR $7.68
- MNTK $13.24
- P/E Ratio
- PHAR N/A
- MNTK $52.03
- Revenue Growth
- PHAR 24.13
- MNTK N/A
- 52 Week Low
- PHAR $6.65
- MNTK $1.68
- 52 Week High
- PHAR $12.61
- MNTK $6.13
- Technical
- Relative Strength Index (RSI)
- PHAR 48.21
- MNTK 67.12
- Support Level
- PHAR $10.46
- MNTK $2.16
- Resistance Level
- PHAR $11.49
- MNTK $2.35
- Average True Range (ATR)
- PHAR 0.37
- MNTK 0.18
- MACD
- PHAR -0.12
- MNTK 0.05
- Stochastic Oscillator
- PHAR 27.62
- MNTK 91.67
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.